GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new ...
Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Abstract: This paper proposes a digital ramp interleaved current-mode constant-on-time (COT) control methodology that eliminates the need for a pulse distributor by utilizing the amplitude of the ramp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results